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IMPORTANCE Patients with estrogen receptor (ER)–positive breast cancer have a long-term
risk for fatal disease. However, the tumor biological factors that influence the long-term risk
and the benefit associated with endocrine therapy are not well understood.
OBJECTIVE To compare the long-term survival from tamoxifen therapy for patients with
luminal A or luminal B tumor subtype.
DESIGN, SETTING, AND PARTICIPANTS Secondary analysis of patients from the Stockholm
Tamoxifen (STO-3) trial conducted from 1976 to 1990, which randomized postmenopausal
patients with lymph node–negative breast cancer to receive adjuvant tamoxifen or no
endocrine therapy. Tumor tissue sections were assessed in 2014 using immunohistochemistry
and Agilent microarrays. Only patients with luminal A or B subtype tumors were evaluated.
Complete long-term follow-up data up to the end of the STO-3 trial on December 31, 2012,
were obtained from the Swedish National registers. Data analysis for the secondary analysis
was conducted in 2017 and 2018.
INTERVENTIONS Patients were randomized to receive at least 2 years of tamoxifen therapy
or no endocrine therapy; patients without recurrence who reconsented were further
randomized to 3 additional years of tamoxifen therapy or no endocrine therapy.
MAIN OUTCOMES AND MEASURES Distant recurrence-free interval (DRFI) by luminal A and
luminal B subtype and trial arm was assessed by Kaplan-Meier analyses and time-dependent
flexible parametric models to estimate time-varying hazard ratios (HRs) that were adjusted
for patient and tumor characteristics.
RESULTS In the STO-3 treated trial arm, 183 patients had luminal A tumors and 64 patients
had luminal B tumors. In the untreated arm, 153 patients had luminal A tumors and 62 had
luminal B tumors. Age at diagnosis ranged from 45 to 73 years. A statistically significant
difference in DRFI by trial arm was observed (log rank, P < .001 [luminal A subtype, n = 336],
P = .04 [luminal B subtype, n = 126]): the 25-year DRFI for luminal A vs luminal B subtypes
was 87% (95% CI, 82%-93%) vs 67% (95% CI, 56%-82%) for treated patients, and 70%
(95% CI, 62%-79%) vs 54% (95% CI, 42%-70%) for untreated patients, respectively.
Patients with luminal A tumors significantly benefited from tamoxifen therapy for 15 years
after diagnosis (HR, 0.57; 95% CI, 0.35-0.94), and those with luminal B tumors benefited
from tamoxifen therapy for 5 years (HR, 0.38; 95% CI, 0.24-0.59).
CONCLUSIONS AND RELEVANCE Patients with luminal A subtype tumors had a long-term risk
of distant metastatic disease, which was reduced by tamoxifen treatment, whereas patients
with luminal B tumors had an early risk of distant metastatic disease, and tamoxifen benefit
attenuated over time.
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Published online August 8, 2019.
Author Affiliations: Author
affiliations are listed at the end of this
article.
Corresponding Author: Linda
Lindström, MSc, PhD, Department of
Biosciences and Nutrition, Karolinska
Institutet, 141 83 Stockholm, Sweden
(linda.lindstrom@ki.se).
Assessment of Long-term Distant Recurrence-Free 
Survival
Associated With Tamoxifen Therapy in Postmenopausal
Patients With Luminal A or Luminal B Breast Cancer
Nancy Y. Yu, PhD; Adina Iftimi, PhD; Christina Yau, PhD; Nicholas P. Tobin, PhD; Laura van ’t Veer, PhD;
Katherine A. Hoadley, PhD; Christopher C. Benz, MD; Bo Nordenskjöld, MD, PhD; Tommy Fornander, MD, PhD;
Olle Stål, PhD; Kamila Czene, PhD; Laura J. Esserman, MD, MBA; Linda S. Lindström, MSc, PhD
B reast tumors can be classified into 5 intrinsic subtypesas measured by mRNA expression,1 with most estrogenreceptor (ER)–positive tumors classified as luminal A or
luminal B subtype. In general, luminal A tumors have higher
ER-expression and lower tumor cell proliferation than luminal
B tumors.2,3 Approximately 1 in 4 patients with ER-positive
breast cancer will develop distant metastasis and eventually die
from the disease,4,5 and it is currently not possible to accu-
rately predict a patient’s long-term risk or the benefit of endo-
crine therapy.
It has been suggested that patients with ER-positive breast
cancer have a long-term risk for fatal breast cancer,5 but little
is known about the tumor biological factors that influence this
long-term risk. Therefore, we investigated the long-term sur-
vival and benefit of endocrine therapy (tamoxifen) for pa-
tients with luminal A or luminal B tumor subtype using data
from the Stockholm Tamoxifen (STO-3) trial, including com-
plete long-term follow-up of patients randomized to receive
adjuvant tamoxifen vs no endocrine therapy.
Methods
The STO-3 Trial
The Stockholm breast cancer study group conducted random-
ized trials from 1976 until 1990.6,7 The STO-3 trial enrolled
postmenopausal patients with lymph node–negative breast
cancer with tumors less than or equal to 30 mm in diameter.
Patients were randomized to receive adjuvant tamoxifen
(40 mg daily) for 2 years vs no adjuvant treatment (Figure 1).
No other adjuvant therapy was given. In 1983, patients who
reconsented and were relapse-free after 2 years of tamoxifen
treatment were randomized to 3 additional years of tamoxifen
therapy or no further therapy (see the eMethods in the
Supplement).
All residents in Sweden have a unique national registra-
tion number that enables automatic linkage of various rec-
ords of personal information from high-quality national and
regional registers and essentially complete coverage. Cancer
registration has a legal basis in Sweden, and the Swedish Can-
cer Registry covers more than 96% of breast cancer cases
according to validation studies.8 Information on metastatic
disease was obtained from the regional Stockholm Breast
Cancer Quality Registry as held by the Regional Cancer Cen-
ter in Stockholm.9 Detailed patient and clinical information
and complete long-term follow-up until December 31, 2012
was available for all patients included in the STO-3 random-
ized trial.
The STO-3 trial, which was conducted at the Regional
Cancer Center Stockholm-Gotland in Stockholm, began in
1976, well before trial registration started in Sweden; there-
fore, information on trial number is not available. The STO-3
trial was approved by the ethical vetting board at Karolinska
Institutet. At the time when the trial was approved and
Key Points
Question What is the long-term survival associated with
tamoxifen therapy for postmenopausal patients with luminal A
or luminal B subtype tumors?
Findings This secondary analysis of the Stockholm Tamoxifen
(STO-3) trial of 462 postmenopausal patients with lymph
node-negative breast cancer found that patients with luminal A
or luminal B tumor subtypes had a long-term risk of distant
metastatic breast cancer and benefited from tamoxifen therapy
for 15 years and 5 years after diagnosis, respectively.
Meaning Patients with luminal A tumor subtype appeared to have
a long-term benefit from tamoxifen therapy, and patients with
luminal B subtype appeared to have an early benefit from therapy,
when the risk of distant metastatic disease was high.
Figure 1. Consort Diagram for the Stockholm Tamoxifen (STO-3) Trial
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started, written consent was not considered ethically
acceptable by the ethical boards in Sweden because it was
thought to disturb the trust of the patient-doctor relation-
ship; thus, only oral consent was accepted, and patients
were orally informed.
ER, PR, ERBB2, and Ki-67 Immunohistochemistry
In 2014, formalin-fixed paraffin-embedded tumor tissue
sections from 727 STO-3 trial participants underwent immu-
nohistochemistry (IHC) analysis at the University of Califor-
nia Davis Medical Center laboratory to detect ER, progester-
one receptor (PR), ERBB2 (formerly human epidermal
growth factor receptor 2), and Ki-67. Gene expression in tis-
sue sections from 652 patients was measured using Agilent
microarrays. Additional details are described in the
eMethods in the Supplement. Breast cancer pathologists at
the University of California, who were part of the ATHENA
Breast Health Network, scored the percentage of cancer
cells positive for ER, PR, ERBB2, and Ki-67 (on whole-tumor
sections with microscopes). A threshold of 10% or greater
was used to define ER and PR positivity (according to the
Swedish national guidelines), ERBB2 positivity was defined
as a score of ≥3 on immunohistochemistry, and the Ki-67
threshold for positivity was 15% or greater.10
Tumor Grade and Intrinsic Subtypes
Tumor grade was retrospectively assessed according to the
Nottingham system according to Elston-Ellis grading
method.11,12 Tumors were assigned to 1 of 5 molecular sub-
types (luminal A, luminal B, ERBB2-enriched, basal-like,
normal-like) using the PAM50 gene expression classification
as described by Parker et al13 (see the e Methods in the
Supplement for details).
Statistical Analyses
Analyses of long-term (25 years) distant recurrence-free
interval (DRFI) were performed for luminal A and luminal B
tumor subtypes by STO-3 trial arm, according to the defini-
tion by Hudis et al.14 The event was distant breast cancer re-
currence. Only patients with ER-positive breast cancer were
included in the analyses because we wanted to investigate the
benefit of endocrine therapy. Patient follow-up started at the
date of primary breast cancer diagnosis and ended at the date
of distant metastatic disease, death, emigration from Swe-
den (only 5 women emigrated), or the end of study follow-up
(December 31, 2012).
Kaplan-Meier analyses were performed for patients with
luminal A or luminal B subtype by STO-3 trial arm (treated vs
untreated). Statistical significance was assessed using the log-
rank test.
Time-varying analyses were performed using flexible
parametric models, where the logarithm of the baseline haz-
ard function was modeled as a natural cubic spline function
of log time.15,16 We modeled this relationship using a 2
degrees-of-freedom spline, adjusting for the classical patient
and tumor characteristics, namely age and calendar period of
breast cancer diagnosis, PR status, Ki-67 status, tumor grade,
and tumor size. We allowed for the effects of both tamoxifen
and luminal subtype to change over the follow-up time (non-
proportional hazards) by including interaction with time,
using natural cubic splines (with 1 degree of freedom). The
time scale in all analyses was the number of years since
breast cancer diagnosis. For model selection, we assessed
the goodness of fit using the Akaike Information Criterion
(AIC) and included a penalty for the number of estimated
parameters.
Data analysis was done from 2017 to 2018 using SAS ver-
sion 9.4 (SAS Institute). Survival analyses and visual repre-
sentations were performed using R version 3.4.3, including
the survival and survminer packages17 (see the eAppendix in
the Supplement). The flexible parametric survival modeling
was performed using the R package rstpm2.16,18 All statistical
tests were 2-sided, and P < .05 was considered statistically
significant.
Results
In the STO-3 treated trial arm, 183 patients had luminal A tu-
mors and 64 patients had luminal B tumors. In the untreated
arm, 153 patients had luminal A tumors and 62 had luminal B
tumors. Age at diagnosis ranged from 45 to 73 years. The
eResults and eTable 1 in the Supplement outline the patient
and tumor characteristics in the STO-3 trial. Patient charac-
teristics such as age and calendar period of primary breast
cancer diagnosis and trial arm distribution did not differ sig-
nificantly between patients with luminal A and luminal B sub-
type. However as would be expected, most tumor character-
istics were significantly different when contrasting luminal A
and luminal B tumors.
Kaplan-Meier Analysis of DRFI
Associated With Tamoxifen Therapy
Kaplan-Meier analyses by trial arm were performed for
patients with luminal A or luminal B tumors (Figure 2). A
statistically significant difference in DRFI (25 years) by trial
arm was seen in both luminal A (log rank, P < .001) and
luminal B (log rank, P = .04) subtypes. The DRFI for luminal
A vs B subtype was 87% (95% CI, 82%-93%) vs 67% (95% CI,
56%-82%) for treated patients, and 70% (95% CI, 62%-79%)
vs 54% (95% CI, 42%-70%) for untreated patients, respec-
tively. For patients with luminal A subtype in both the
tamoxifen treated and untreated arm, a risk for distant
metastasis was observed throughout 25 years of follow-up
(Figure 2A). The long-term risk was also seen for patients
with luminal B tumors treated with tamoxifen, in contrast
to untreated patients with luminal B tumors whose level of
risk was high during the first 5 years and then declined
(Figure 2B).
Time-Varying Multivariable Analysis of Long-term Distant
Recurrence-Free Survival Associated With Tamoxifen
We used flexible parametric modeling to perform a time-
varying analysis of the long-term benefit of tamoxifen therapy
for patients with luminal A or luminal B tumors, adjusting
for classic patient and tumor characteristics (age, calendar
period of breast cancer diagnosis, PR status, Ki-67 status,
tumor grade, and tumor size) in addition to crude estimates
(only adjusting for age and calendar period of breast cancer
diagnosis). Crude and adjusted analysis yielded similar
results (eTable 2 in the Supplement). Consistent with the
Kaplan-Meier analysis, a risk of distant recurrence was
observed throughout 25 years of follow-up in patients with
luminal A tumors (Figure 3). The estimated hazard rate for
patients with luminal A tumors reached a peak hazard rate at
around 5 years after diagnosis and later stabilized throughout
the 25-year follow-up (Figure 3A). Furthermore, the findings
from the time-varying hazard ratio (HR) analysis (Figure 3C;
eTable 2 in the Supplement) suggested that patients with
luminal A subtype in the treated arm had a significant benefit
from tamoxifen for 15 years (HR at 15 years, 0.57; 95% CI,
0.35-0.94) compared with patients in the untreated arm (see
eTable 2 in the Supplement).
Treated patients with luminal B tumors had a lower early
risk compared with that of untreated luminal B patients; how-
ever, the ongoing risk (estimated hazard rate) of distant recur-
rence for treated and untreated patients with luminal B tu-
mors converged after 10 to 15 years (Figure 3B). Untreated
patients with luminal B tumors had a high early risk during the
first 5 to 10 years after diagnosis, but the risk declined steeply
and reached the risk level of untreated patients with luminal
A tumors approximately 10 years after diagnosis (Figure 3B).
Treated patients with luminal B tumors had a risk of distant
metastasis similar to that of untreated patients with luminal
A tumors, which peaked at around 5 years after diagnosis, and
remained the same throughout the 25-year follow-up. Fi-
nally, findings from the time-varying HR analysis suggested
that patients in the treated arm with luminal B subtype ben-
efited from tamoxifen (Figure 3D; eTable 2 in the Supple-
ment) for 5 years (HR at 5 years, 0.38; 95% CI, 0.24-0.59) com-
pared with patients in the untreated arm (see eTable 2 in the
Supplement).
Discussion
In this study, we used data from the STO-3 trial of patients ran-
domized to receive adjuvant tamoxifen vs no endocrine
therapy to investigate long-term survival and benefit associ-
ated with tamoxifen therapy for patients with lymph node–
negative, ER-positive, luminal A or luminal B subtype tu-
mors. To our knowledge, this study is the first to show that
patients with luminal A subtype tumors had a risk of distant
metastatic disease throughout a 25-year follow-up period, and
the findings from the time-varying analysis suggested that pa-
tients in the treated arm had a long-term benefit from tamox-
ifen therapy that attenuated by 15 years. In addition, for un-
treated patients with luminal B tumors, less than half
experienced the risk of distant metastatic disease in the first
5 years after diagnosis, and the risk stabilized and precipi-
tously declined 5 years after diagnosis. Interestingly, patients
with luminal B subtype in the treated arm had a risk of dis-
tant metastatic disease throughout the follow-up period, simi-
lar to untreated patients with luminal A subtype. The find-
ings from the time-varying analysis also suggested that benefit
from tamoxifen in patients with luminal B subtype was great-
est in the first 5 years and then attenuated; by 10 years, the risk
in treated and untreated patients was the same.
The long-term benefit of tamoxifen therapy for patients
with luminal A or luminal B subtype tumors has been un-
known up to now. However, it has been suggested that pa-
tients with luminal B tumor subtype may benefit less from en-
docrine therapy compared with patients with luminal A
subtype,2 supporting our current findings of long-term ben-
efit for patients with luminal A subtype and short-term ben-
efit for patients with luminal B subtype. There is a biological
rationale for the suggested differences in benefit. For in-
stance, luminal A tumors in general have lower proliferation
rates and are more likely to be purely ER-driven; therefore,












































































Log-rank P = .04
Kaplan-Meier analyses of distant recurrence-free survival interval by Stockholm Tamoxifen (STO-3) trial arm (tamoxifen treated vs untreated arm) for patients with
(A) luminal A and (B) luminal B tumor subtypes. The P value is based on a 2-sided log-rank test. DRFI indicates distant recurrence-free interval.
patients with this tumor subtype can potentially benefit lon-
ger from tamoxifen therapy.19,20 In contrast, luminal B
tumors often have higher proliferation rates that, in addition
to the ER-signaling pathway, may be driven by multiple
active oncogenic pathways; therefore, these tumors might be
less amendable to endocrine therapy.1,19-22 Patients with
luminal A or luminal B subtype tumors should be offered
adjuvant endocrine therapy. In patients with luminal B sub-
type, up-front chemotherapy should be discussed and endo-
crine therapy potentially extended for up to 10 years, particu-
larly in those in the higher risk strata according to other
tumor characteristics.
Limitations
The present secondary analysis of the STO-3 trial assessed
long-term survival in the trial cohort from 1976 until 1990.
There are several limitations to our study. As with most
long-term follow up studies, clinical recommendations for
disease management and treatment have changed since the
initiation of the trial. The STO-3 trial was performed before
aromatase inhibitors became one of the recommended
treatment options for ER-positive breast cancer and when
the duration of tamoxifen treatment was shorter than cur-
rent recommendations. In this population-based trial of
patients with lymph-node negative breast cancer, the num-
ber of patients with luminal B subtype tumors was lower
than the number of patients with luminal A tumors due to
tumor biology; therefore, analyses of patients with luminal
B subtype are limited in statistical power. In addition, for
patients with luminal B tumors, current treatment recom-
mendations generally include chemotherapy.
Conclusions
We conclude that tamoxifen appears to confer a long-term
benefit for patients with lymph node–negative, ER-positive,
luminal A subtype tumors, and a short-term benefit for
patients with luminal B subtype tumors. Given that the risk
of distant metastatic disease is low for patients with the lu-
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Estimated time-dependent hazard rates of distant recurrence for treated vs
untreated patients with luminal A (A) or luminal B (B) subtypes. Estimated
hazard ratio by tamoxifen treated vs untreated trial arm for patients with
luminal A (C) or luminal B (D) subtypes. The untreated group is the reference.
Shading indicates the 95% CI.
minal A subtype but persists in the long term, whereas the risk
for patients with luminal B subtype is higher initially but de-
creases after 5 years, tamoxifen treatment is beneficial for pa-
tients with luminal A or luminal B subtype tumors.
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